北京天坛生物制品股份有限公司 生物技术 | 央企 | 1000人以上 | https://www.tiantanbio.com/

单位介绍

    北京天坛生物制品股份有限公司（简称“天坛生物”，股票代码：600161.SH）于1998年上市，主营业务为血液制品的研发、制造、销售及咨询服务。经过2010年、2017年两次重大资产重组后，天坛生物成为中国生物旗下唯一的血液制品专业公司。天坛生物下辖成都蓉生、兰州血制、上海血制、武汉血制、贵州血制五家血液制品生产企业，在全国十三个省、自治区拥有50余个单采血浆采集基地，生产规模处于国内领先地位。天坛生物也是国内最早开始从事血液制品工业化生产的企业，其血液制品生产历史可追溯至1966年，目前拥有人血白蛋白、人免疫球蛋白、人凝血因子Ⅷ三大类产品，共计14个品种71个产品生产文号。天坛生物拥有一批多年从事血浆蛋白产品研发的科技人员，技术实力雄厚。天坛生物旗下的血液制品企业在国内血液制品行业占据多个第一，在国内首发上市人血白蛋白、静注人免疫球蛋白（pH4）、破伤风人免疫球蛋白等产品，率先引进血浆蛋白压滤分离工艺，建立了血浆蛋白产品、病毒灭活工艺技术验证和重组产品的研发平台。目前，天坛生物产品品种数量在国内稳居前列，生产的血液制品在国内市场中占有较大市场份额，拥有质量、规模及品牌等方面的综合优势，致力于为社会提供更多品种、更多数量和更优质量的血液制品，努力成为中国领先、国际一流的血液制品企业。
    Beijing Tiantan Biological Products Co., Ltd. (hereinafter referred to as "TiantanBio", stock code: 600161. SH) was listed in 1998. Its main business is research and development, manufacturing, sales and consulting services of blood products. After two major asset restructuring in 2010 and 2017, TiantanBio has become the only professional blood products company under China National Biotec Group Co., Ltd. TiantanBio has 5 blood manufacturers, including Chengdu Rongsheng, Lanzhou Blood Product, Shanghai Blood Product, Wuhan Blood Product and Guizhou Blood Product. It has more than 50 plasma collection bases in 13 provinces and autonomous regions of China, and its production scale is in the leading position in China. TiantanBio is also the first enterprise in China to engage in the industrial production of blood products. Its production history of blood products can be traced back to 1966. At present, it has three categories of products: human albumin, human immunoglobulin and human coagulation factor VIII, with a total of 14 varieties and 71 product licenses. TiantanBio has a group of scientific and technical personnel who have been engaged in the research and development of plasma protein products for many years and have strong technical strength. Those blood manufacturers belong to TiantanBio occupy many firsts in the domestic blood products industry, products such as human albumin, intravenous injection of human immunoglobulin (pH4) and tetanus human immunoglobulin were first listed in China. The plasma protein pressure filtration separation process was first introduced, and a research and development platform for plasma protein products, virus inactivation process technology verification and recombinant products was established. At present, the number of TiantanBio’s products is firmly in the forefront in China. The blood products produced occupy a large market share in the domestic market and have comprehensive advantages in quality, scale and brand. We are committed to providing more varieties, more quantities and better quality blood products for the society and strive to become China's leading and international first-class blood products enterprise.